Boston Scientific Corp (BSX) 12.51 $BSX
Texas Jury awards $73 Million in Pelvic Mesh Case, announces Matthews & Associates
PR Newswire - Wed Sep 10, 3:58PM CDT
A 12-person jury on Monday ordered Boston Scientific Corp. to pay a Texas woman $73 million after finding the company negligent in both the design and marketing of its Obtryx transvaginal mesh sling.
Watch for Boston Scientific to Potentially Pullback After Gaining 1.05% Yesterday
Comtex SmarTrend(R) - Wed Sep 10, 3:56PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $12.35 to a high of $12.55. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $12.45 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Boston Scientific to Potentially Pullback after Yesterday's 1.05% Rise
Comtex SmarTrend(R) - Wed Sep 10, 3:56PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $12.35 to a high of $12.55. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $12.45 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
pSivida Corp. Names James Barry to Board of Directors
Business Wire - Wed Sep 10, 3:00PM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has elected James J. Barry, Ph.D. to its Board of Directors.
Boston Scientific Announces Schedule For Presentations At Upcoming TCT 2014
PR Newswire - Wed Sep 10, 8:00AM CDT
Beginning Saturday, Boston Scientific Corporation (NYSE: BSX) will present data that reinforce the company's commitment to advancing science for life and to developing innovative therapies in interventional cardiology. The company will share results from more than a dozen clinical studies at the 26th Transcatheter Cardiovascular Therapeutics (TCT) meeting, the annual scientific symposium of the Cardiovascular Research Foundation, being held this year in Washington, D.C. from September 13-17.
Market Maker Surveillance Report. WEN, BSX, MO, BA, MSFT, ORCL, Highest Net Buy Volume With Lowest Price Friction For Tuesday, September 9th 2014
M2 - Wed Sep 10, 3:39AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4670 companies with "abnormal" market making, 1404 companies with positive Friction Factors and 3746 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Tuesday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Wendy's Company (NASDAQ:WEN), Boston Scientific Corp (NYSE:BSX), Altria Group Inc (NYSE:MO), Boeing Co (NYSE:BA), MICROSOFT CORPORATION (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Halloran Consulting Group Expands Services with Physician, Safety Expert, and Head of Regulatory Affairs
Business Wire - Tue Sep 09, 9:00AM CDT
Halloran Consulting Group, Inc. (Halloran) today announced the recent hiring of Greg Shipp, MD, formerly with Regenesis Biomedical where he served as Director of Clinical Research; Laura Giannini, RPh, MBA, previously with Boston Scientific as Director of Process Management; and Mary Matthew, formerly with ZIOPHARM Oncology where she served as Vice President of Regulatory Affairs and Quality.
Coronary Stents Market in India 2014
M2 - Tue Sep 09, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qnbgv/coronary_stents) has announced the addition of the "Coronary Stents Market in India 2014" report to their offering. Advancements in technology has resulted in patients being more receptive towards stent implants. The products available in the market can be divided into two types - those manufactured by MNCs and commanding high prices, and those manufactured by domestic companies and generally having lower prices. The general perception is that stents manufactured by MNCs are superior in terms of quality and efficacy whereas those manufactured by domestic companies fail to attain similar high quality. As a result, the MNCs serve majority of the market with almost all the big hospitals in tier I cities preferring to implant stents manufactured by foreign companies. Since the medical equipments and devices industry in India has not been given any separate legal status and coronary stents have been classified as drugs under the provisions of the Drugs & Cosmetics Act, 1940, the Central Drugs Standard Control Organization (CDSCO) is responsible for the regulation of stents in the country. The significant reduction in reimbursement rates for stents under the Central Government Health Scheme (CGHS) in Feb 2013 and a further reduction in the reimbursement rates in Apr 2014 has badly affected manufacturers, especially the MNCs. Key Topics Covered: - Executive Summary - Macroeconomic Indicators - Introduction - Market Overview - Drivers & Challenges - Government Involvement - Competitive Landscape - Buyer Details - Recent Developments - Strategic Recommendation - Appendix Companies Mentioned Public Companies: - Opto Circuits (India) Ltd. Private Companies - Abbott Healthcare Pvt. Ltd. - B. Braun Medical (India) Pvt. Ltd. - Boston Scientific India Pvt. Ltd. - India Medtronic Pvt. Ltd. - MIV Therapeutics (India) Pvt. Ltd. - Meril Life Sciences Pvt. Ltd. - Relisys Medical Devices Ltd. - Sahajanand Medical Technologies Pvt. Ltd. - Vascular Concepts Ltd. For more information visit http://www.researchandmarkets.com/research/8q...ary_stents
Transvaginal Mesh Lawsuit News: Pennsylvania Court Denies Manufacturers' Bid to Have Mesh Suits Dismissed, The Rottenstein Law Group LLP Reports
PRWeb - Mon Sep 08, 2:03PM CDT
The preliminary objections of defendant vaginal mesh manufacturers Boston Scientific Corp., Ethicon Inc., Johnson & Johnson, C.R. Bard Inc., and American Medical Systems Inc. were overruled without prejudice by the Court of Common Pleas, First Judicial District of Pennsylvania (Philadelphia) on September 2, according to an order of the court filed in In re: Pelvic Mesh Litigation (case no. 140200829). The mesh manufacturers may still seek summary judgment on a case-by-case basis.
Boston Scientific (BSX) Approaches New Upside Target of $12.34
Comtex SmarTrend(R) - Mon Sep 08, 9:28AM CDT
Shares of Boston Scientific (NYSE:BSX) opened today above their pivot of $12.08 and have already reached the first level of resistance at $12.18. Investors may be interested in a cross of the next upside pivot targets of $12.34 and $12.60.
Australia Peripheral Vascular & Cardiovascular Procedures Devices Market Outlook to 2020 New Report Available at MarketOptimizer.org
PRWeb - Sun Sep 07, 8:30PM CDT
Australia Peripheral Vascular Devices Market Outlook to 2020
Boston Scientific Set to Possibly Rebound After Yesterday's Selloff of 1.88%
Comtex SmarTrend(R) - Fri Sep 05, 3:44PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $11.99 to a high of $12.25. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $12.18 on volume of 31.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Boston Scientific After 1.88% Loss
Comtex SmarTrend(R) - Fri Sep 05, 3:43PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $11.99 to a high of $12.25. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $12.18 on volume of 31.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Abbott Labs' Weakness in Devices Hurts Long-Term Growth Potential
at The Street - Fri Sep 05, 5:00AM CDT
There's no compelling reason to buy this stock above $40.
Boston Scientific (BSX) Crosses Pivot Point Support at $12.35
Comtex SmarTrend(R) - Thu Sep 04, 10:13AM CDT
Shares of Boston Scientific (NYSE:BSX) opened today below their pivot of $12.51 and have already reached the first level of support at $12.35. Should the shares continue to fall, the support pivots of $12.26 and $12.01 will be of interest.
Insider Trading Alert - NNN, WDAY And BSX Traded By Insiders
at The Street - Thu Sep 04, 9:31AM CDT
Stocks with insider trader activity include NNN, WDAY and BSX
Critical Alerts For Mobileye NV, YPF, Boston Scientific, VIVUS and Juniper Networks Released By InvestorsObserver
PR Newswire - Thu Sep 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, YPF, BSX, VVUS and JNPR.
Technical Updates, Clinical Trial Results, Certifications, Product Launches, and Grants - Research Reports on Avalonbay, Digital Realty, Boston Scientific, Agilent and Cigna
PR Newswire - Thu Sep 04, 7:40AM CDT
Today, Analysts Review released its research reports regarding Avalonbay Communities Inc. (NYSE: AVB), Digital Realty Trust Inc. (NYSE: DLR), Boston Scientific Corporation (NYSE: BSX), Agilent Technologies Inc. (NYSE: A) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6195-100free.
BostonScientific Posts NECTAR-HF Trial Data, Shares Drop - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 2:20PM CDT
The NECTAR-HF trial is the first and only randomized clinical trial examining the efficacy of Boston Scientific's (BSX) investigational vagal nerve stimulation (VNS) device.
Global Heart Valve Repair and Replacement Market 2014-2018 - Key Vendors are Abbott Laboratories, Edward Lifesciences, Medtronic & St. Jude Medical
M2 - Wed Sep 03, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4bq7ck/global_heart) has announced the addition of the "Global Heart Valve Repair and Replacement Market 2014-2018" report to their offering. The Global Heart Valve Repair and Replacement market to grow at a CAGR of 7.72 percent over the period 2013-2018. Heart valves are structures in the human heart which control the flow of blood during the cardiac cycle. A person affected with heart valve diseases such as valvular stenosis, valvular insufficiency or regurgitation, prolapse, and atresia requires the repair or replacement of the natural heart valves. Aortic valves cannot be repaired; therefore, it is replaced using prosthetic heart valves. However, the mitral, tricuspid, and pulmonary valves can be repaired as well as replaced depending on the diseased condition and functionality of these valves. Heart valve repair and replacement devices are used for repairing the diseased heart valves as well as for replacing the natural valves with prosthetic valves. One of the emerging trends in the market is the increase in the number of products approved by regulatory authorities such as the FDA and CE. Such products are considered to be safe for commercial use increasing their adoption rate. According to the report, the increase in the aging population is one of the major drivers in the market. The incidence of cardiac disorders is more prevalent among the aging population across the world and people above the age of 60 years affected by heart valve diseases is expected to contribute to the growth the market. Further, the report states that the potential risk of complications associated with the use of heart valve repair and replacement devices is proving to be a barrier to the adoption of these devices. Some of the complications are device migration, infection, thrombosis, and mortality. In terms of application, the Global Heart Valve Repair and Replacement market can be segmented into two: - Heart Valve Repair - Heart Valve Replacement Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Key Vendors - Abbott Laboratories - Edward Lifesciences - Medtronic - St. Jude Medical Other Prominent Vendors - AorTech - Boston Scientific - Colibri Heart Valve - CryoLife - Direct Flow Medical - JenaValve - MiCardia - Mitralign - Neovasc - On-X Life Technologies - Sorin - Symentis - ValveXchange For more information visit http://www.researchandmarkets.com/research/4b...obal_heart
Texas Jury awards $73 Million in Pelvic Mesh Case, announces Matthews & Associates
PR Newswire - Wed Sep 10, 3:58PM CDT
A 12-person jury on Monday ordered Boston Scientific Corp. to pay a Texas woman $73 million after finding the company negligent in both the design and marketing of its Obtryx transvaginal mesh sling.
Watch for Boston Scientific to Potentially Pullback After Gaining 1.05% Yesterday
Comtex SmarTrend(R) - Wed Sep 10, 3:56PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $12.35 to a high of $12.55. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $12.45 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Boston Scientific to Potentially Pullback after Yesterday's 1.05% Rise
Comtex SmarTrend(R) - Wed Sep 10, 3:56PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $12.35 to a high of $12.55. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $12.45 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
pSivida Corp. Names James Barry to Board of Directors
Business Wire - Wed Sep 10, 3:00PM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has elected James J. Barry, Ph.D. to its Board of Directors.
Boston Scientific Announces Schedule For Presentations At Upcoming TCT 2014
PR Newswire - Wed Sep 10, 8:00AM CDT
Beginning Saturday, Boston Scientific Corporation (NYSE: BSX) will present data that reinforce the company's commitment to advancing science for life and to developing innovative therapies in interventional cardiology. The company will share results from more than a dozen clinical studies at the 26th Transcatheter Cardiovascular Therapeutics (TCT) meeting, the annual scientific symposium of the Cardiovascular Research Foundation, being held this year in Washington, D.C. from September 13-17.
Market Maker Surveillance Report. WEN, BSX, MO, BA, MSFT, ORCL, Highest Net Buy Volume With Lowest Price Friction For Tuesday, September 9th 2014
M2 - Wed Sep 10, 3:39AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4670 companies with "abnormal" market making, 1404 companies with positive Friction Factors and 3746 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Tuesday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Wendy's Company (NASDAQ:WEN), Boston Scientific Corp (NYSE:BSX), Altria Group Inc (NYSE:MO), Boeing Co (NYSE:BA), MICROSOFT CORPORATION (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Halloran Consulting Group Expands Services with Physician, Safety Expert, and Head of Regulatory Affairs
Business Wire - Tue Sep 09, 9:00AM CDT
Halloran Consulting Group, Inc. (Halloran) today announced the recent hiring of Greg Shipp, MD, formerly with Regenesis Biomedical where he served as Director of Clinical Research; Laura Giannini, RPh, MBA, previously with Boston Scientific as Director of Process Management; and Mary Matthew, formerly with ZIOPHARM Oncology where she served as Vice President of Regulatory Affairs and Quality.
Coronary Stents Market in India 2014
M2 - Tue Sep 09, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qnbgv/coronary_stents) has announced the addition of the "Coronary Stents Market in India 2014" report to their offering. Advancements in technology has resulted in patients being more receptive towards stent implants. The products available in the market can be divided into two types - those manufactured by MNCs and commanding high prices, and those manufactured by domestic companies and generally having lower prices. The general perception is that stents manufactured by MNCs are superior in terms of quality and efficacy whereas those manufactured by domestic companies fail to attain similar high quality. As a result, the MNCs serve majority of the market with almost all the big hospitals in tier I cities preferring to implant stents manufactured by foreign companies. Since the medical equipments and devices industry in India has not been given any separate legal status and coronary stents have been classified as drugs under the provisions of the Drugs & Cosmetics Act, 1940, the Central Drugs Standard Control Organization (CDSCO) is responsible for the regulation of stents in the country. The significant reduction in reimbursement rates for stents under the Central Government Health Scheme (CGHS) in Feb 2013 and a further reduction in the reimbursement rates in Apr 2014 has badly affected manufacturers, especially the MNCs. Key Topics Covered: - Executive Summary - Macroeconomic Indicators - Introduction - Market Overview - Drivers & Challenges - Government Involvement - Competitive Landscape - Buyer Details - Recent Developments - Strategic Recommendation - Appendix Companies Mentioned Public Companies: - Opto Circuits (India) Ltd. Private Companies - Abbott Healthcare Pvt. Ltd. - B. Braun Medical (India) Pvt. Ltd. - Boston Scientific India Pvt. Ltd. - India Medtronic Pvt. Ltd. - MIV Therapeutics (India) Pvt. Ltd. - Meril Life Sciences Pvt. Ltd. - Relisys Medical Devices Ltd. - Sahajanand Medical Technologies Pvt. Ltd. - Vascular Concepts Ltd. For more information visit http://www.researchandmarkets.com/research/8q...ary_stents
Transvaginal Mesh Lawsuit News: Pennsylvania Court Denies Manufacturers' Bid to Have Mesh Suits Dismissed, The Rottenstein Law Group LLP Reports
PRWeb - Mon Sep 08, 2:03PM CDT
The preliminary objections of defendant vaginal mesh manufacturers Boston Scientific Corp., Ethicon Inc., Johnson & Johnson, C.R. Bard Inc., and American Medical Systems Inc. were overruled without prejudice by the Court of Common Pleas, First Judicial District of Pennsylvania (Philadelphia) on September 2, according to an order of the court filed in In re: Pelvic Mesh Litigation (case no. 140200829). The mesh manufacturers may still seek summary judgment on a case-by-case basis.
Boston Scientific (BSX) Approaches New Upside Target of $12.34
Comtex SmarTrend(R) - Mon Sep 08, 9:28AM CDT
Shares of Boston Scientific (NYSE:BSX) opened today above their pivot of $12.08 and have already reached the first level of resistance at $12.18. Investors may be interested in a cross of the next upside pivot targets of $12.34 and $12.60.
Australia Peripheral Vascular & Cardiovascular Procedures Devices Market Outlook to 2020 New Report Available at MarketOptimizer.org
PRWeb - Sun Sep 07, 8:30PM CDT
Australia Peripheral Vascular Devices Market Outlook to 2020
Boston Scientific Set to Possibly Rebound After Yesterday's Selloff of 1.88%
Comtex SmarTrend(R) - Fri Sep 05, 3:44PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $11.99 to a high of $12.25. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $12.18 on volume of 31.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Boston Scientific After 1.88% Loss
Comtex SmarTrend(R) - Fri Sep 05, 3:43PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $11.99 to a high of $12.25. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $12.18 on volume of 31.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Abbott Labs' Weakness in Devices Hurts Long-Term Growth Potential
at The Street - Fri Sep 05, 5:00AM CDT
There's no compelling reason to buy this stock above $40.
Boston Scientific (BSX) Crosses Pivot Point Support at $12.35
Comtex SmarTrend(R) - Thu Sep 04, 10:13AM CDT
Shares of Boston Scientific (NYSE:BSX) opened today below their pivot of $12.51 and have already reached the first level of support at $12.35. Should the shares continue to fall, the support pivots of $12.26 and $12.01 will be of interest.
Insider Trading Alert - NNN, WDAY And BSX Traded By Insiders
at The Street - Thu Sep 04, 9:31AM CDT
Stocks with insider trader activity include NNN, WDAY and BSX
Critical Alerts For Mobileye NV, YPF, Boston Scientific, VIVUS and Juniper Networks Released By InvestorsObserver
PR Newswire - Thu Sep 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, YPF, BSX, VVUS and JNPR.
Technical Updates, Clinical Trial Results, Certifications, Product Launches, and Grants - Research Reports on Avalonbay, Digital Realty, Boston Scientific, Agilent and Cigna
PR Newswire - Thu Sep 04, 7:40AM CDT
Today, Analysts Review released its research reports regarding Avalonbay Communities Inc. (NYSE: AVB), Digital Realty Trust Inc. (NYSE: DLR), Boston Scientific Corporation (NYSE: BSX), Agilent Technologies Inc. (NYSE: A) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6195-100free.
BostonScientific Posts NECTAR-HF Trial Data, Shares Drop - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 2:20PM CDT
The NECTAR-HF trial is the first and only randomized clinical trial examining the efficacy of Boston Scientific's (BSX) investigational vagal nerve stimulation (VNS) device.
Global Heart Valve Repair and Replacement Market 2014-2018 - Key Vendors are Abbott Laboratories, Edward Lifesciences, Medtronic & St. Jude Medical
M2 - Wed Sep 03, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4bq7ck/global_heart) has announced the addition of the "Global Heart Valve Repair and Replacement Market 2014-2018" report to their offering. The Global Heart Valve Repair and Replacement market to grow at a CAGR of 7.72 percent over the period 2013-2018. Heart valves are structures in the human heart which control the flow of blood during the cardiac cycle. A person affected with heart valve diseases such as valvular stenosis, valvular insufficiency or regurgitation, prolapse, and atresia requires the repair or replacement of the natural heart valves. Aortic valves cannot be repaired; therefore, it is replaced using prosthetic heart valves. However, the mitral, tricuspid, and pulmonary valves can be repaired as well as replaced depending on the diseased condition and functionality of these valves. Heart valve repair and replacement devices are used for repairing the diseased heart valves as well as for replacing the natural valves with prosthetic valves. One of the emerging trends in the market is the increase in the number of products approved by regulatory authorities such as the FDA and CE. Such products are considered to be safe for commercial use increasing their adoption rate. According to the report, the increase in the aging population is one of the major drivers in the market. The incidence of cardiac disorders is more prevalent among the aging population across the world and people above the age of 60 years affected by heart valve diseases is expected to contribute to the growth the market. Further, the report states that the potential risk of complications associated with the use of heart valve repair and replacement devices is proving to be a barrier to the adoption of these devices. Some of the complications are device migration, infection, thrombosis, and mortality. In terms of application, the Global Heart Valve Repair and Replacement market can be segmented into two: - Heart Valve Repair - Heart Valve Replacement Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Key Vendors - Abbott Laboratories - Edward Lifesciences - Medtronic - St. Jude Medical Other Prominent Vendors - AorTech - Boston Scientific - Colibri Heart Valve - CryoLife - Direct Flow Medical - JenaValve - MiCardia - Mitralign - Neovasc - On-X Life Technologies - Sorin - Symentis - ValveXchange For more information visit http://www.researchandmarkets.com/research/4b...obal_heart
